Patent Application
20090318523
This invention relates to indole derivatives, to processes for their preparation, to pharmaceutical compositions containing them and to their use in medicine.
The compounds of the present invention are EP4 receptor agonists.
A number of review articles describe the characterization and therapeutic relevance of the prostanoid receptors as well as the most commonly used selective agonists and antagonists: Eicosanoids; From Biotechnology to Therapeutic Applications, Folco, Samuelsson, Maclouf, and Velo eds, Plenum Press, New York, 1996, chap. 14, 137-154 and Journal of Lipid Mediators and Cell Signalling, 1996, 14, 83-87 and Prostanoid Receptors, Structure, Properties and Function, S Narumiya et al, Physiological Reviews 1999, 79(4), 1193-126.
The EP4 receptor is a 7-transmembrane receptor and its natural ligand is the prostaglandin PGE2. PGE2 also has affinity for the other EP receptors (types EP1, EP2 and EP3). The prostanoid EP4 receptor falls into a group of receptors normally associated with elevation of intracellular cyclic adenosine monophosphate (cAMP) levels. The EP4 receptor is associated with smooth muscle relaxation, intraocular pressure, pain (in particular inflammatory, neuropathic and visceral pain), inflammation, neuroprotection, lymphocyte differentiation, bone metabolic processes, allergic activities, promotion of sleep, renal regulation, gastric or enteric mucus secretion and duodenal bicarbonate secretion. The EP4 receptor plays an important role in closure of the ductus arteriosus, vasodepression, inflammation and bone remodeling as reviewed by Narumiya in Prostaglandins & Other Lipid Mediators 2002, 68-69 557-73.
A number of publications have demonstrated that PGE2 acting through the EP4 receptor subtype, and EP4 agonists alone, can regulate inflammatory cytokines after an inflammatory stimulus. Takayama et al in the Journal of Biological Chemistry 2002, 277(46), 44147-54 showed PGE2 modulates inflammation during inflammatory diseases by suppressing macrophage derived chemokine production via the EP4 receptor. In Bioorganic & Medicinal Chemistry 2002, 10(7), 2103-2110, Maruyama et al demonstrate the selective EP4 receptor agonist (ONO-AE1-437) suppresses LPS induced TNF-α in human whole blood whilst increasing the levels of IL-10. An article in Anesthesiology, 2002, 97, 170-176 suggests that a selective EP4 receptor agonist (ONO-AE1-329) effectively inhibited mechanical and thermal hyperalgesia and inflammatory reactions in acute and chronic monoarthritis.
Two independent articles from Sakuma et al in Journal of Bone and Mineral Research 2000, 15(2), 218-227 and Miyaura et al in Journal of Biological Chemistry 2000, 275(26), 19819-23, report impaired osteoclast formation in cells cultured from EP4 receptor knock-out mice. Yoshida et al in Proceedings of the National Academy of Sciences of the United States of America 2002, 99(7), 4580-4585, by use of mice lacking each of the PGE2 receptor EP subtypes, identified EP4 as the receptor that mediates bone formation in response to PGE2 administration. They also demonstrated a selective EP4 receptor agonist (ONO-4819) consistently induces bone formation in wild type mice. Additionally, Terai et al in Bone 2005, 37(4), 555-562 have shown the presence of a selective EP4 receptor agonist (ONO-4819) enhanced the bone-inducing capacity of rhBMP-2, a therapeutic cytokine that can induce bone formation.
Further research by Larsen et al shows the effects of PGE2 on secretion in the second part of the human duodenum is mediated through the EP4 receptor (Acta. Physiol. Scand. 2005, 185, 133-140). Also, it has been shown a selective EP4 receptor agonist (ONO-AE1-329) can protect against colitis in rats (Nitta et al in Scandinavian Journal of Immunology 2002, 56(1), 66-75).
Doré et al in The European Journal of Neuroscience 2005, 22(9), 2199-206 have shown that PGE2 can protect neurons against amyloid beta peptide toxicity by acting on EP2 and EP4 receptors. Furthermore Doré has demonstrated in Brain Research 2005, 1066(1-2), 71-77 that an EP4 receptor agonist (ONO-AE1-329) protects against neurotoxicity in an acute model of excitotoxicity in the brain.
Woodward et al in Journal of Lipid Mediators 1993, 6(1-3), 545-53 found intraocular pressure could be lowered using selective prostanoid agonists. Two papers in Investigative Opthalmology & Visual Science have shown the prostanoid EP4 receptor is expressed in human lens epithelial cells (Mukhopadhyay et al 1999, 40(1), 105-12), and suggest a physiological role for the prostanoid EP4 receptor in modulation of flow in the trabecular framework of the eye (Hoyng et al 1999, 40(11), 2622-6).
Compounds exhibiting EP4 receptor binding activity have been described in, for example, WO98/55468, WO00/18744, WO00/03980, WO00/15608, WO0016760, WO00/21532, EP0855389, EP0985663, WO02/50031, WO02/50032, WO02/50033, WO02/064564, WO03/103604, WO03/077910, WO03/086371, WO04/037813, WO04/067524, WO04/085430, U.S. Pat. No. 4,142,969, WO05/021508, WO05/105733, WO05/105732, WO05/080367, WO05/037812, WO05/116010, and WO 06/122403
Derivatives of indoprofen such as [4-(1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl)phenyl]-2-propionic acid, sodium salt have been described by Rufer et. al. in Eur. J. Med. Chem.—Chimica Therapeutica, 1978, 13, 193.
Compounds of the present invention have been shown to have advantageous in vivo and in vitro activities when tested in the biological assays described herein.
The present invention provides a compound selected from the group consisting of:
In a further embodiment of the invention there is provided an EP4 agonist selected from the group consisting of:
By pharmaceutically acceptable derivative is meant any pharmaceutically acceptable salt, solvate or ester, or salt or solvate of such ester of the compounds of the invention, or any other compound which upon administration to the recipient is capable of providing (directly or indirectly) a compound of the invention or an active metabolite or residue thereof.
It will be appreciated that, for pharmaceutical use, the salts referred to above will be the pharmaceutically acceptable salts, but other salts may find use, for example in the preparation of compounds of the invention and the pharmaceutically acceptable salts thereof.
Pharmaceutically acceptable salts include those described by Berge, Bighley and Monkhouse, J. Pharm. Sci., 1977, 66, 1-19. The term “pharmaceutically acceptable salts” refers to salts prepared from pharmaceutically acceptable bases including inorganic bases and organic bases. Salts derived from inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic salts, manganous, potassium, sodium, zinc, and the like. Salts derived from pharmaceutically acceptable organic bases include salts of primary, secondary, and tertiary amines; substituted amines including naturally occurring substituted amines; and cyclic amines. Particular pharmaceutically acceptable organic bases include arginine, betaine, caffeine, choline, N,N′-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethyl-morpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, procaine, purines, theobromine, triethylamine, trimethylamine, tripropyl amine, tris(hydroxymethyl)aminomethane, and the like. Salts may also be formed from basic ion exchange resins, for example polyamine resins.
It will be appreciated that the compounds of the invention may be produced in vivo by metabolism of a suitable prodrug. Such prodrugs may be for example physiologically acceptable metabolically labile esters of the compounds of the invention. These may be formed by esterification of the carboxylic acid group in the parent compound of the invention with, where appropriate, prior protection of any other reactive groups present in the molecule followed by deprotection if required. Examples of such metabolically labile esters include C1-4 alkyl esters e.g. methyl ethyl or t-butyl esters esters, C3-6 alkenyl esters e.g. allyl substituted or unsubstituted aminoalkyl esters (e.g. aminoethyl, 2-(N,N-diethylamino) ethyl, or 2-(4-morpholino)ethyl esters or acyloxyalkyl esters such as, acyloxymethyl or 1-acyloxyethyl e.g. pivaloyloxymethyl, 1-pivaloyloxyethyl, acetoxymethyl, 1-acetoxyethyl, 1-(1-methoxy-1-methyl)ethylcarbonyloxyethyl, 1-benzoyloxyethyl, isopropoxycarbonyloxymethyl, 1-isopropoxycarbonyloxyethyl, cyclohexylcarbonyloxymethyl, 1-cyclohexylcarbonyloxyethyl ester, cyclohexyloxycarbonyloxymethyl, 1-cyclohexyloxycarbonyloxyethyl, 1-(4-tetrahydropyranyloxy)carbonyloxyethyl or 1-(4-tetrahydropyranyl)carbonyloxyethyl.
It is to be understood that the present invention encompasses all isomers of the compounds of the invention and their pharmaceutically acceptable derivatives, including all geometric, tautomeric and optical forms, and mixtures thereof (e.g. racemic mixtures).
Since the compounds of the invention are intended for use in pharmaceutical compositions, it will be understood that they are each provided in substantially pure form, for example at least 50% pure, more suitably at least 75% pure and preferably at least 95% pure (% are on a wt/wt basis). Impure preparations of the compounds of the invention may be used for preparing the more pure forms used in the pharmaceutical compositions. Although the purity of intermediate compounds of the present invention is less critical, it will be readily understood that the substantially pure form is preferred as for the compounds of the invention. Preferably, whenever possible, the compounds of the present invention are obtained in crystalline form.
When some of the compounds of this invention are allowed to crystallise or are recrystallised from organic solvents, solvent of crystallisation may be present in the crystalline product. This invention includes within its scope such solvates. Similarly, some of the compounds of this invention may be crystallised or recrystallised from solvents containing water. In such cases water of hydration may be formed. This invention includes within its scope stoichiometric hydrates as well as compounds containing variable amounts of water that may be produced by processes such as lyophilisation. In addition, different crystallisation conditions may lead to the formation of different polymorphic forms of crystalline products. This invention includes within its scope all polymorphic forms of the compounds of the invention.
The present invention also includes within its scope all isotopically-labelled compounds of the invention. Such compounds are identical to those recited in the list of the compounds of the invention except that one or more atoms therein are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into compounds of the invention and pharmaceutically acceptable derivatives thereof include isotopes of hydrogen, carbon, nitrogen, oxygen and fluorine, such as 2H, 3H, 11C, 13C, 14C, 15N, 17O, 18O and 18F.
Isotopically-labelled compounds of the invention, for example those into which radioactive isotopes such as 3H, 14C are incorporated, are useful in drug and/or substrate tissue distribution assays. Tritiated, i.e., 3H, and carbon-14, i.e., 14C, isotopes are particularly preferred for their ease of preparation and detectability 11C and 18F isotopes are particularly useful in PET (positron emission tomography) and are useful in brain imaging. Further substitution with heavier isotopes such as deuterium, i.e., 2H, can afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements and, hence, may be preferred in some circumstances. Isotopically labelled compounds of the invention may be prepared by carrying out the synthetic procedures disclosed in the Schemes and/or in the Examples below, by substituting a readily available isotopically labelled reagent for a non-isotopically labelled reagent.
The compounds of the invention are EP4 receptor agonists and may therefore be useful in treating EP4 receptor mediated diseases.
In particular the compounds of the invention may be useful in the treatment of pain, for example, chronic articular pain (e.g. rheumatoid arthritis, osteoarthritis, rheumatoid spondylitis, gouty arthritis and juvenile arthritis) including the property of disease modification and joint structure preservation; musculoskeletal pain; lower back and neck pain; sprains and strains; neuropathic pain; sympathetically maintained pain; myositis; pain associated with cancer and fibromyalgia; pain associated with migraine; pain associated with influenza or other viral infections, such as the common cold; rheumatic fever; pain associated with functional bowel disorders such as non-ulcer dyspepsia, non-cardiac chest pain and irritable bowel syndrome; pain associated with myocardial ischemia; post operative pain; headache; toothache; and dysmenorrhea.
The compounds of the invention may be particularly useful in the treatment of neuropathic pain and symptoms associated therewith. Neuropathic pain syndromes include: diabetic neuropathy; sciatica; non-specific lower back pain; multiple sclerosis pain; fibromyalgia; HIV-related neuropathy; post-herpetic neuralgia; trigeminal neuralgia; and pain resulting from physical trauma, amputation, cancer, toxins or chronic inflammatory conditions. Symptoms of neuropathic pain include spontaneous shooting and lancinating pain, or ongoing, burning pain. In addition, there is included pain associated with normally non-painful sensations such as “pins and needles” (paraesthesias and dysesthesias), increased sensitivity to touch (hyperesthesia), painful sensation following innocuous stimulation (dynamic, static or thermal allodynia), increased sensitivity to noxious stimuli (thermal, cold, mechanical hyperalgesia), continuing pain sensation after removal of the stimulation (hyperpathia) or an absence of or deficit in selective sensory pathways (hypoalgesia).
The compounds of the invention may also be useful in the treatment of inflammation, for example in the treatment of skin conditions (e.g. sunburn, burns, eczema, dermatitis, psoriasis); ophthalmic diseases such as glaucoma, retinitis, retinopathies, uveitis and of acute injury to the eye tissue (e.g. conjunctivitis); lung disorders (e.g. asthma, bronchitis, emphysema, allergic rhinitis, respiratory distress syndrome, pigeon fancier's disease, farmer's lung, COPD); gastrointestinal tract disorders (e.g. aphthous ulcer, Crohn's disease, atopic gastritis, gastritis varialoforme, ulcerative colitis, coeliac disease, regional ileitis, irritable bowel syndrome, inflammatory bowel disease, gastrointestinal reflux disease, diarrhoea, constipation); organ transplantation; other conditions with an inflammatory component such as vascular disease, migraine, periarteritis nodosa, thyroiditis, aplastic anaemia, Hodgkin's disease, sclerodoma, myaesthenia gravis, multiple sclerosis, sorcoidosis, nephrotic syndrome, Bechet's syndrome, polymyositis, gingivitis, myocardial ischemia, pyrexia, systemic lupus erythematosus, polymyositis, tendinitis, bursitis, and Sjogren's syndrome.
The compounds of the invention may also be useful in the treatment of immunological diseases such as autoimmune diseases, immunological deficiency diseases or organ transplantation. The compounds of the invention may also be effective in increasing the latency of HIV infection.
The compounds of the invention may also be useful in the treatment of diseases of excessive or unwanted platelet activation such as intermittent claudication, unstable angina, stroke, and acute coronary syndrome (e.g. occlusive vascular diseases).
The compounds of the invention may also be useful as a drug with diuretic action, or may be useful to treat overactive bladder syndrome.
The compounds of the invention may also be useful in the treatment of impotence or erectile dysfunction.
The compounds of the invention may also be useful in the treatment of bone disease characterised by abnormal bone metabolism or resorption such as osteoporosis (especially postmenopausal osteoporosis), hyper-calcemia, hyperparathyroidism, Paget's bone diseases, osteolysis, hypercalcemia of malignancy with or without bone metastases, rheumatoid arthritis, periodontitis, osteoarthritis, ostealgia, osteopenia, calculosis, lithiasis (especially urolithiasis), gout and ankylosing spondylitis, tendinitis and bursitis.
The compounds of the invention may also be useful in bone remodelling and/or promoting bone generation and/or promoting fracture healing.
The compounds of the invention may also be useful for attenuating the hemodynamic side effects of NSAIDs and COX-2 inhibitors.
The compounds of the invention may also be useful in the treatment of cardiovascular diseases such as hypertension or myocardial ischemia; functional or organic venous insufficiency; varicose therapy; haemorrhoids; and shock states associated with a marked drop in arterial pressure (e.g. septic shock).
The compounds of the invention may also be useful in the treatment of neurodegenerative diseases and neurodegeneration such as dementia, particularly degenerative dementia (including senile dementia, Alzheimer's disease, Pick's disease, Huntingdon's chorea, Parkinson's disease and Creutzfeldt-Jakob disease, ALS, motor neuron disease); vascular dementia (including multi-infarct dementia); as well as dementia associated with intracranial space occupying lesions; trauma; infections and related conditions (including HIV infection); metabolism; toxins; anoxia and vitamin deficiency; and mild cognitive impairment associated with ageing, particularly Age Associated Memory Impairment.
The compounds of the invention may also be useful in the treatment of neurological disorders and may be useful as neuroprotecting agents. The compounds of the invention may also be useful in the treatment of neurodegeneration following stroke, cardiac arrest, pulmonary bypass, traumatic brain injury, spinal cord injury or the like.
The compounds of the invention may also be useful in the treatment of complications of Type 1 diabetes (e.g. diabetic microangiopathy, diabetic retinopathy, diabetic nephropathy, macular degeneration, glaucoma), nephrotic syndrome, aplastic anaemia, uveitis, Kawasaki disease and sarcoidosis.
The compounds of the invention may also be useful in the treatment of kidney dysfunction (nephritis, particularly mesangial proliferative glomerulonephritis, nephritic syndrome), liver dysfunction (hepatitis, cirrhosis) and gastrointestinal dysfunction (diarrhoea).
It is to be understood that reference to treatment includes both treatment of established symptoms and prophylactic treatment.
According to a further embodiment of the invention, there is provided a compound of the invention or a pharmaceutically acceptable derivative thereof for use in human or veterinary medicine.
According to another embodiment of the invention, there is provided a compound of the invention or a pharmaceutically acceptable derivative thereof for use in the treatment of a condition which is mediated by the action, or loss of action, of PGE2 at EP4 receptors.
According to a further embodiment of the invention, there is provided a method of treating a human or animal subject suffering from a condition which is mediated by the action, or by loss of action, of PGE2 at EP4 receptors which comprises administering to said subject an effective amount of a compound of the invention or a pharmaceutically acceptable derivative thereof.
According to a further embodiment of the invention there is provided a method of treating a human or animal subject suffering from a pain, inflammatory, immunological, bone, neurodegenerative or renal disorder, which method comprises administering to said subject an effective amount of a compound of the invention or a pharmaceutically acceptable derivative thereof.
According to another embodiment of the invention, there is provided the use of a compound of the invention or a pharmaceutically acceptable derivative thereof for the manufacture of a medicament for the treatment of a condition which is mediated by the action of PGE2 at EP4 receptors.
According to another embodiment of the invention there is provided the use of a compound of the invention or a pharmaceutically acceptable derivative thereof for the manufacture of a medicament for the treatment or prevention of a condition such as a pain, inflammatory, immunological, bone, neurodegenerative or renal disorder.
The compounds of the invention and their pharmaceutically acceptable derivatives are conveniently administered in the form of pharmaceutical compositions. Such compositions may conveniently be presented for use in conventional manner in admixture with one or more physiologically acceptable carriers or excipients.
Thus, in another aspect of the invention, there is provided a pharmaceutical composition comprising a compound of the invention or a pharmaceutically acceptable derivative thereof adapted for use in human or veterinary medicine.
While it is possible for the compounds of the invention or a pharmaceutically acceptable derivative thereof to be administered as the raw chemical, it is preferable to present it as a pharmaceutical formulation. The formulations of the present invention comprise the compounds of the invention or a pharmaceutically acceptable derivative thereof together with one or more acceptable carriers or diluents therefor and optionally other therapeutic ingredients. The carrier(s) must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
The formulations include those suitable for oral, parenteral (including subcutaneous e.g. by injection or by depot tablet, intradermal, intrathecal, intramuscular e.g. by depot and intravenous), rectal and topical (including dermal, buccal and sublingual) administration although the most suitable route may depend upon for example the condition and disorder of the recipient. The formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. (see for example methods disclosed in ‘Remington—The Science and Practice of Pharmacy’, 21st Edition, Lippincoft, Williams & Wilkins, USA, 2005 and references therein). All methods include the step of bringing into association the compound of the invention or a pharmaceutically acceptable acid addition salt thereof (“active ingredient”) with the carrier which constitutes one or more accessory ingredients. In general the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both and then, if necessary, shaping the product into the desired formulation.
Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets (e.g. chewable tablets in particular for paediatric administration) each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion. The active ingredient may also be presented as a bolus, electuary or paste.
A tablet may be made by compression or moulding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, lubricating, surface active or dispersing agent. Moulded tablets may be made by moulding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent. The tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active ingredient therein.
Formulations for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilised) condition requiring only the addition of a sterile liquid carrier, for example, water-for-injection, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.
Formulations for rectal administration may be presented as a suppository with the usual carriers such as cocoa butter, hard fat or polyethylene glycol.
Formulations for topical administration in the mouth, for example buccally or sublingually, include lozenges comprising the active ingredient in a flavoured basis such as sucrose and acacia or tragacanth, and pastilles comprising the active ingredient in a basis such as gelatin and glycerin or sucrose and acacia.
The compounds of the invention may also be formulated as depot preparations. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds of the invention may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
In addition to the ingredients particularly mentioned above, the formulations may include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include flavouring agents.
The EP4 receptor compounds for use in the present invention may be used in combination with other therapeutic agents, for example COX-2 inhibitors, such as celecoxib, rofecoxib, valdecoxib or parecoxib; 5-lipoxygenase inhibitors; analgesics such as paracetamol; NSAID's, such as diclofenac, indomethacin, nabumetone, naproxen or ibuprofen; leukotriene receptor antagonists; DMARD's such as methotrexate; sodium channel blockers, such as lamotrigine; N-type calcium channel antagonists; NMDA receptor modulators, such as glycine receptor antagonists; gabapentin, pregabalin and related compounds; tricyclic antidepressants such as amitriptyline; neurone stabilising antiepileptic drugs; mono-aminergic uptake inhibitors such as venlafaxine; opioid analgesics; local anaesthetics; 5HT1 agonists, such as triptans, for example sumatriptan, naratriptan, zolmitriptan, eletriptan, frovatriptan, almotriptan or rizatriptan; EP1 receptor ligands; EP2 receptor ligands; EP3 receptor ligands; EP1 antagonists; EP2 antagonists and EP3 antagonists; cannabanoid receptor agonists; VR1 antagonists. When the compounds are used in combination with other therapeutic agents, the compounds may be administered either sequentially or simultaneously by any convenient route.
The invention thus provides, in a further embodiment, a combination comprising a compound of the invention or a pharmaceutically acceptable derivative thereof together with a further therapeutic agent or agents. In one embodiment of the invention there is provided a combination comprising a compound of the invention or a pharmaceutically acceptable derivative thereof and paracetamol.
The combinations referred to above may conveniently be presented for use in the form of a pharmaceutical formulation and thus pharmaceutical formulations comprising a combination as defined above together with a pharmaceutically acceptable carrier or excipient comprise a further aspect of the invention. In particular there is provided a pharmaceutical composition comprising a compound of the invention or a pharmaceutically acceptable derivative thereof, paracetamol and a pharmaceutically acceptable carrier or diluent therefor. The individual components of such combinations may be administered either sequentially or simultaneously in separate or combined pharmaceutical formulations.
When a compound of the invention or a pharmaceutically acceptable derivative thereof is used in combination with a second therapeutic agent active against the same disease, the dose of each compound may differ from that when the compound is used alone. Appropriate doses will be readily appreciated by those skilled in the art.
A proposed daily dosage of a compound of the invention, or a pharmaceutically acceptable salt thereof, for the treatment of man is from 0.001 to 30 mg/kg body weight per day and more particularly 0.1 to 3 mg/kg body weight per day, calculated as the free acid, which may be administered as a single or divided dose, for example one to four times per day. The dose range for adult human beings is generally from 0.1 to 1000 mg/day, such as from 10 to 800 mg/day, preferably 10 to 200 mg/day, calculated as the free acid.
A suitable daily dosage of paracetamol is up to 4000 mg per day. Suitable unit doses include 200, 400, 500 and 1000 mg, one, two, three or four times per day.
The precise amount of the compounds of the invention administered to a host, particularly a human patient, will be the responsibility of the attendant physician. However, the dose employed will depend on a number of factors including the age and sex of the patient, the precise condition being treated and its severity, the route of administration, and any possible combination therapy that may be being undertaken.
The compounds of the invention may be prepared according to Schemes 1a, 1b and 1c in which they are denoted generally as “Formula (I)”.
As used in Schemes 1a, 1b and 1c,
R1 represents C1-4 alkyl;
R represents C1-4 alkyl or CH2Ph;
R2 and R3 independently represent C1-4 alkyl or CH2Ph;
R4 represents C1-4 alkyl, C1-4 alkoxy or CF3;
R5 represents C1-6 alkyl;
R6 represents C1-4 alkyl;
m and n independently represent 0 or 1; and
In Scheme 1a, where R2 and R3 are different step ii is carried out as a two step process in which R2 is added and then R3, or vice versa.
As used herein, the term ‘C1-4 alkyl’ includes straight chain and branched chain alkyl groups containing 1 to 4 carbon atoms, such as methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl and tert-butyl. The term ‘C1-6 alkyl’ may be interpreted accordingly.
Compounds of formula (I) are commercially available or may be prepared in accordance with methods known in the art. For example, methyl dimethylphthalate may be purchased from Sigma-Aldrich Co. Ltd.
Compounds of formula (A) are commercially available or may be prepared in accordance with methods known in the art. For example, diethyl succinate may be purchased from Sigma-Aldrich Co. Ltd.
The reaction between compounds of formula (I) and compounds of formula (A) may be performed in accordance with the method disclosed in International Patent Application, Publication Number WO 02/064564.
Compounds of formula (B) may be prepared according to Scheme 2:
where, (i) NaH, dry DMF or DMSO; (ii) NH4CO2H, EtOH, Pd/C; or Pd/C, H2 followed by NaOH, then HCl, then EtOH/PhMe/PTSA; wherein R4 and R5 are as defined in relation to Schemes 1a, 1b and 1c and R7 represents C1-4 alkyl or CH2Ph.
As used in Scheme 2, X represents halo, for example F or Cl.
Compounds of formula (4) are commercially available or may be prepared in accordance with methods known in the art. For example, 5-fluoro-2-nitrobenzeneotrifluoride and 5-fluoro-2-nitrotoluene and 5-chloro-2-nitroanisole may be purchased from Sigma-Aldrich Co. Ltd.
Compounds of formula (5) are commercially available or may be prepared in accordance with methods known in the art. For example, benzyl ethyl malonate and dimethyl malonate may be purchased from Sigma-Aldrich Co. Ltd.
The following Descriptions and Examples illustrate the preparation of the compounds of the invention. Descriptions refer to intermediate compounds.
EtOAc Ethyl acetate
HCl Hydrochloric acid
LC/MS Liquid chromatography/Mass spectroscopy
LHMDS Lithium hexamethyldisylazide
MDAP Mass directed auto preparation
PTSA p-toluene sulfonic acid
TFA Trifluoroacetic acid
Waters Atlantis (4.6 mm×50 mm). Stationary phase particle size, 3 μm.
A: Aqueous solvent=Water+0.05% Formic Acid
B: Organic solvent=Acetonitrile+0.05% Formic Acid
All retention times are measured in minutes.
Purification of the Examples may be carried out by conventional methods such as chromatography and/or recrystallisation using suitable solvents. Chromatographic methods include column chromatography, flash chromatography, HPLC (high performance liquid chromatography), SFC (supercritical fluid chromatography), and MDAP (mass directed autopreparation).
The term “Biotage” when used herein refers to commercially available pre-packed silica gel cartridges.
Waters Atlantis: 19 mm×100 mm (small scale); and 30 mm×100 mm (large scale).
Stationary phase particle size, 5 μm.
A: Aqueous solvent=Water+0.1% Formic Acid
B: Organic solvent=Acetonitrile+0.1% Formic Acid
Make up solvent=Methanol:Water 80:20
Needle rinse solvent=Methanol
Five methods were used depending on the analytical retention time of the compound of interest:
Runtime, 13.5 minutes, comprising 10-minute gradient followed by a 3.5 minute column flush and re-equilibration step.
Runtime, 13.5 minutes, comprising 6-minute gradient followed by a 7.5 minute column flush and re-equilibration step.
20 mls/min (Small Scale) or 40 mls/min (Large Scale).
Berger Ethyl-Pyridine column (150 mm×21.2 mm ID; 6 micron)
A=Carbon dioxide and B=Methanol
Isocratic @ A:B (85:15 v/v); Flow=50 mLmin-1; 35° C.; 100 bar
Detection by U.V. absorbance at 220 nm
Injection volume: 250 uL
Chiralcel OD (250 mm×20 mm ID; 10 micron)
A=Carbon dioxide and B=Methanol
Isocratic @ A:B (75:25 v/v); Flow=50 mLmin-1; 35° C.; 100 bar
Detection by U.V. absorbance at 215 nm
Injection volume: 1 mL
Chiralcel OD (250 mm×20 mm ID; 10 micron)
Isocratic @ A:B (70:30 v/v); Ambient temperature.
Detection by U.V. absorbance at 215 nm
ID=internal diameter
Methyl dimethylphthalate (10 g, 48 mmol) and LHMDS (1M in hexanes, 196 ml, 192 mmol) in THF (150 ml) were cooled to 0° C. Diethyl succinate (15.9 ml, 96 mmol) was added dropwise over 20 minutes (maximum internal temperature 4° C.). Allowed to warm to room temperature. After 4 hours, 1M HCl (˜500 ml) was added and the aqueous was extracted with EtOAc (×2), all the combined organics washed with brine, dried over magnesium sulphate and concentrated in vacuo to give an orange oil. This was purified by chromatography on silica gel eluting with ethyl acetate/hexane (2:98) to yield the title compound as a white solid (3.03 g, 9.5 mmol). LC/MS: Rt=3.51.
1-Bromopropane (13.1 ml, 144.4 mmol) was added to a stirring solution of diethyl 1,4-dihydroxy-2,3-naphthalenedicarboxylate* (11 g, 36.1 mmol) and potassium carbonate (24.9 g, 180.5 mmol) in acetone (180 ml). Refluxed overnight under an atmosphere of argon. The resulting mixture was cooled, filtered and the solvent evaporated from the filtrate. The residue was taken up in toluene and washed with 5% potassium hydroxide solution, brine and dried over magnesium sulphate. Purified by chromatography on silica gel eluting with ethyl acetate/hexane (1:9) to give the title compound as yellow oil (11.45 g, 29.5 mmol). LC/MS: Rt=3.87, [MH]+ 389. *1,4-dihydroxy-2,3-naphthalenedicarboxylate may be prepared in accordance with the method disclosed in International Patent Application, Publication Number WO02/064564.
The following compounds were prepared in a similar manner to diethyl 1,4-bis(propyloxy)-2,3-naphthalenedicarboxylate using the appropriate starting materials.
A mixture of diethyl 1,4-bis(propyloxy)-2,3-naphthalenedicarboxylate (11.45 g, 29:5 mmol), ethanol (70 ml), sodium hydroxide (3.54 g, 88.5 mmol) and water (15 ml) was refluxed for 4 hours. The reaction mixture was cooled and evaporated to a third of the volume. This was acidified with hydrochloric acid (2N) and extracted with ethyl acetate (3×100 ml). Combined organics washed with water, brine and dried over magnesium sulphate. Solvent was evaporated to give the title compound as a yellow solid (8.91 g, 26.8 mmol). LC/MS: Rt=2.74, [MH]+ 333.
The following compounds were prepared in a similar manner to 1,4-bis(propyloxy)-2,3-naphthalenedicarboxylic acid using the appropriate starting materials.
Thionyl chloride (20.5 ml, 281.4 mmol) was added dropwise to a solution of 1,4-bis(propyloxy)-2,3-naphthalenedicarboxylic acid (8.91 g, 26.8 mmol) in chloroform (80 ml) and heated at 65° C. for 2.5 hours. The reaction mixture was cooled and solvent evaporated to yellow solid. Azeotroped with chloroform to give the title compound as a beige solid (8.74 g, 103% yield). LC/MS: Rt=3.77, [MH]+ 315.
The following compounds were prepared in a similar manner to 4,9-bis(propyloxy)naphtho[2,3-c]furan-1,3-dione using the appropriate starting materials.
Sodium hydride (60% in oil, 8.73 g, 2.2 eq) was washed with 40-60 petroleum ether (×2) then DMSO (225 ml) was added followed by dimethylmalonate (25 ml, 2.2 eq) in portions. After addition the mixture was heated to 10° C. for 30 minutes then cooled to room temperature overnight. The next day, 5-chloro-2-nitroanisole (18.61 g, 1 eq) was added and the solution heated to 100° C. (internal). After 3 hours further sodium malonate (0.6 eq) {dimethylmalonate (6.8 ml) and sodium hydride (2.38 g) in DMSO (60 ml)} was added, plus further 5-chloro-2-nitroanisole (2.71 g) and further dimethylmalonate (4 ml). After 17 hours heating, the solution was cooled; acetic acid (18 ml) added and then poured onto water (700 ml) in portions. Extracted with diethyl ether/petroleum ether 40-60 (1:1, 4×140 ml), then with DCM/cyclohexane (2:1). Organics combined and excess dimethyl malonate distilled off in vacuo to give a dark red oil (˜30 g). Purified by silica gel chromatography (DCM) to give oil (˜20.4 g) which was further purified twice by silica gel chromatography (CHCl3, then DCM) to give the title compound as a yellow solid (11.56 g).
Dimethyl [3-(methyloxy)-4-nitrophenyl]propanedioate (19.65 g) and 10% Pd on charcoal (1.3 g) was stirred under hydrogen in a mix of EtOH, acetic acid and CHCl3 (400 ml). After a few hours, concentrated HCl (4 ml) was added and the mixture stirred under hydrogen overnight. The catalyst was filtered and EtOH (250 ml) added, followed by NaOH (6.3 g) in water (60 ml) to give a dark solution (solvents had been degassed with N2). Stood at room temperature for 2 days then diluted with further EtOH and acidified with concentrated HCl. Heated under reflux for 2 hours, then evaporated in vacuo to dryness, water (350 ml) added and extracted with CHCl3 (×3). Organics evaporated in vacuo to dryness, treated with aqueous NaOH over the weekend at room temperature, evaporated to dryness again, aqueous HCl added and heated at 90° C. for 75 minutes, before evaporating to dryness again. Isolation of acid proved difficult, so ethyl ester was formed: all aqueous fractions were combined, evaporated to dryness, then suspended in a mixture of toluene (40 ml) and EtOH (140 ml) with toluene sulfonic acid (catalyst) and heated under reflux with a Dean Stark head attached for 7 hours. Cooled and evaporated in vacuo, water added, then basified with solid NaHCO3. Extracted with CHCl3 and evaporated in vacuo to give a black oil (6.9 g). Purified by silica gel chromatography (DCM) to give a brown oil (3.78 g). Treated in CHCl3 with HCl in dioxane and evaporated to dryness to give the title compound as the HCl salt (4.21 g). LC/MS: Rt=2.15, [M+] 209.
Sodium hydride (382 mg, 9.6 mmol) was added portionwise to an ice bath chilled solution of benzyl ethyl malonate (2.1 g, 9.6 mmol) in dry DMF (20 ml) and stirred for 10 minutes. At room temperature 5-fluoro-2-nitrobenzenotrifluoride (2 g, 9.6 mmol) was added and stirred under argon. Heated at 100° C. overnight. The reaction mixture was cooled and partitioned between 2N hydrochloric acid (75 ml) and ethyl acetate (75 ml). The aqueous layer was extracted with ethyl acetate (2×75 ml) and the combined organics were evaporated to a yellow oil. Purified by chromatography on silica gel eluting with ethyl acetate/hexane (1:4) to give the title compound as a yellow oil (1.23 g, 3.0 mmol). LC/MS: Rt=3.53, [MH]-410.
The following compound was prepared in a similar manner to ethyl phenylmethyl [4-nitro-3-(trifluoromethyl)phenyl]propanedioate using the appropriate starting materials.
Ethyl phenylmethyl [4-nitro-3-(trifluoromethyl)phenyl]propanedioate (2.1 g, 5.0 mmol) dissolved in ethanol (30 ml), was treated with ammonium formate (3.16 g, 50.1 mmol) and palladium on carbon 10% paste (200 mg) was added under argon. The reaction mixture was refluxed for 3 hours, cooled and filtered. Evaporated and purified by chromatography on silica gel eluting with ethyl acetate/hexane (1:4) to give the title compound as a yellow oil (490 mg, 1.98 mmol). LC/MS: Rt=2.70, [MH]+ 248.
The following compound was prepared in a similar manner to ethyl [4-amino-3-(trifluoromethyl)phenyl]acetate, using the appropriate starting materials.
4,9-Bis(propyloxy)naphtho[2,3-c]furan-1,3-dione (200 mg, 0.6 mmol) dissolved in acetic acid (2 ml), was treated with ethyl (4-amino-3-methylphenyl)acetate (245 mg, 1.2 mmol) and heated at reflux overnight. The reaction mixture was cooled and diluted with ethyl acetate and water. Aqueous phase was extracted with ethyl acetate (×2). Combined organics were washed with brine and dried over magnesium sulphate. Evaporated and purified by chromatography on silica gel eluting with ethyl acetate/hexane (1:5) to give an orange oil, which was triturated in methanol to give the title compound as a white solid (264 mg, 0.5 mmol). LC/MS: Rt=4.13, [MH]+ 490.
The following compounds were prepared in a similar manner to ethyl {4-[1,3-dioxo-4,9-bis(propyloxy)-1,3-dihydro-2H-benzo[f]isoindol-2-yl]-3-methylphenyl}acetate using the appropriate starting materials. Some of these compounds were prepared in the presence of DMAP and powdered molecular sieves (4A) to drive the reactions to completion, then purified with a recrystallisation from isopropanol (denoted by *)
1,4-Bis(ethyloxy)-6-methyl-2,3-naphthalenedicarboxylic acid (0.1 g, 0.3 mmol), ethyl (4-aminophenyl)acetate (130 mg, 0.63 mmol) and 4A powdered molecular sieves (120 mg) were suspended in N-methylpyrrolidine (1 ml) in a microwave vial, sealed and heated in a microwave at 150° C. for 30 minutes. Cooled, diluted with EtOAc and washed with water. The aqueous was extracted with further EtOAc. The combined organics were washed with 2M HCl, brine, dried (MgSO4), and concentrated in vacuo. Chromatography purification was carried out (10 g SiO2, elution with 5-30% EtOAc in hexanes) to yield the title compound as an off white solid (105 mg, 75%). LC/MS: Rt=3.88, [MH]+ 462.
Ethyl {4-[1,3-dioxo-4,9-bis(propyloxy)-1,3-dihydro-2H-benzo[f]isoindol-2-yl]-3-methylphenyl}acetate (39 mg, 0.08 mmol) was suspended in glacial acetic acid (2 ml) and 2N hydrochloric acid (2 ml), and heated until complete, (50-110° C., for 70 hours). Cooled and water was added. The white precipitate which formed was filtered, washed with water, collected and dried in a vacuum oven overnight. (15 mg, 0.03 mmol) LC/MS: Rt=3.71, [MH]+ 462.
The following compounds were prepared in a similar manner to {4-[1,3-dioxo-4,9-bis(propyloxy)-1,3-dihydro-2H-benzo[f]isoindol-2-yl]-3-methylphenyl}acetic acid using the appropriate staring materials. Some of the final compounds required MDAP purification (denoted by *). Where no precipitate was formed on addition of water, an ethyl acetate extraction was achieved to recover the final product (denoted by #)
Ethyl {4-[1,3-dioxo-4,9-bis(propyloxy)-1,3-dihydro-2H-benzo[f]isoindol-2-yl]-3-methylphenyl}acetate (200 mg, 0.4 mmol) was suspended in methanol (3 ml) and tetrahydrofuran (1 ml) added to the solution. Cooled to 0° C. in an ice bath and treated with sodium borohydride (46 mg, 1.22 mmol) portionwise over 2 minutes. Stirred under argon for 1 hour at 0° C. Solvent evaporated and the residue was partitioned between ethyl acetate and 1M ammonium chloride solution. The aqueous layer was extracted with ethyl acetate (×2). Combined organics washed with brine and dried over magnesium sulphate. Organics evaporated to give the title compound (215 mg, 0.43 mmol) LC/MS: Rt=3.70, [MH]+ 492.
The following compounds were prepared in a similar manner to, ethyl {4-[1-hydroxy-3-oxo-4,9-bis(propyloxy)-1,3-dihydro-2H-benzo[f]isoindol-2-yl]-3-methylphenyl}acetate using the appropriate starting materials. Some compounds were prepared in the presence of ethanol to accelerate the reaction (denoted by *).
Ethyl {4-[1-hydroxy-3-oxo-4,9-bis(propyloxy)-1,3-dihydro-2H-benzo[f]isoindol-2-yl]-3-methylphenyl}acetate (215 mg, 0.4 mmol) was dissolved in trifluoroacetic acid (3 ml) and cooled in an ice bath to 0° C. Treated with triethylsilane (0.10 ml, 0.65 mmol) and stirred at 0° C. for 1 hour. Volatiles evaporated and purified directly by chromatography on silica gel eluting with ethyl acetate/hexane (1:4). MDAP purification followed to give the title compound as a white solid (29 mg, 0.06 mmol). LC/MS: Rt=4.05, [MH]+ 476.
The following compounds were prepared in a similar manner to ethyl {3-methyl-4-[1-oxo-4,9-bis(propyloxy)-1,3-dihydro-2H-benzo[f]isoindol-2-yl]phenyl}acetate using the appropriate starting materials.
Ethyl {3-methyl-4-[1-oxo-4,9-bis(propyloxy)-1,3-dihydro-2H-benzo[f]isoindol-2-yl]phenyl}acetate (29 mg, 0.06 mmol) was dissolved in ethanol (3 ml) and treated with 2N sodium hydroxide (1 ml). Heated to reflux for two hours then cooled, and the solvent evaporated. The residue was acidified with 2N hydrochloric acid to pH1. The solid precipitate was filtered, washed with water and dried in a vacuum oven overnight, to give the title compound as a white solid (23 mg, 0.05 mmol). LC/MS: Rt=3.61, [MH]+ 448.
The following compounds were prepared in a similar manner to {3-methyl-4-[1-oxo-4,9-bis(propyloxy)-1,3-dihydro-2H-benzo[f]isoindol-2-yl]phenyl}acetic acid using the appropriate starting materials.
Bromoethane (0.359 g, 3.29 mmol) was added to a stirred solution of diethyl 1,4-dihydroxy-2,3-naphthalenedicarboxylate (1 g, 3.29 mmol) and potassium carbonate (0.454 g, 3.29 mmol) in acetone (25 ml). The reaction mixture was refluxed for 24 hours under an atmosphere of argon. The resulting mixture was evaporated and the residue was partitioned between 2× ethylacetate and water. The combined organics were washed with water and dried over magnesium sulphate. The orange oil was purified by chromatography on silica gel, eluting with ethyl acetate (0-10%) in hexane to give the title compound as a clear oil (0.661 g, 1.99 mmol). LC/MS: Rt=3.63, [MH]− 331.
The following compounds were prepared in a similar manner to diethyl 1-(ethyloxy)-4-hydroxy-2,3-naphthalenedicarboxylate using the appropriate alkylating agent, methyl iodide and 2-bromo propane.
Benzyl bromide (1.32 ml, 11.1 mmol) was added to a stirred solution of diethyl 1-(ethyloxy)-4-hydroxy-2,3-naphthalenedicarboxylate (2.45 g, 7.38 mmol) and potassium carbonate (1.53 g, 11.1 mmol) in acetone (50 ml). The reaction mixture was refluxed for 1 hour under an atmosphere of argon. The resulting mixture was evaporated and the residue was partitioned between 2× ethylacetate and brine. The combined organics were washed with water and dried over magnesium sulphate. The clear oil was purified by chromatography on silica gel, eluting with ethyl acetate (0-40%) in hexane to give the title compound as clear oil (3.05 g, 7.23 mmol). LC/MS: Rt=3.77, [MH]+ 423.
The following compounds were prepared in a similar manner to diethyl 1-(ethyloxy)-4-[(phenylmethyl)oxy]-2,3-naphthalenedicarboxylate using the appropriate starting materials.
A mixture of diethyl 1-(ethyloxy)-4-[(phenylmethyl)oxy]-2,3-naphthalenedicarboxylate (3.05 g, 7.23 mmol), ethanol (30 ml), and 2N aqueous sodium hydroxide solution (35 ml) was refluxed for 3 hours. The reaction mixture was cooled and evaporated. This was acidified with HCl (2N) and extracted with 2× ethyl acetate. Combined organics were dried over magnesium sulphate and the solvent evaporated to give the title compound as a white solid (2.55 g, 6.97 mmol). LC/MS: Rt=2.76, [MH]− 365.
The following compounds were prepared in a similar manner to 1-(ethyloxy)-4-[(phenylmethyl)oxy]-2,3-naphthalenedicarboxylic acid using the appropriate starting materials.
A mixture of 1-(ethyloxy)-4-[(phenylmethyl)oxy]-2,3-naphthalenedicarboxylic acid (2.55 g, 6.97 mmol) and ethyl (4-aminophenyl)acetate (2.49 g, 13.9 mmol) were heated to 120° C. in acetic acid (20 ml) for 18 hours. The reaction mixture was diluted with brine and extracted with 2× ethyl acetate. Combined organics were washed with water then dried over magnesium sulphate, the solvent evaporated to give a brown oil. This was purified by chromatography on silica gel, eluting with ethyl acetate (0-30%) in hexane to give the title compound as a peach coloured solid (2.63 g, 5.17 mmol). LC/MS: Rt=3.95, [MH]+ 510.
The following compounds were prepared in a similar manner to ethyl (4-{4-(ethyloxy)-1,3-dioxo-9-[(phenylmethyl)oxy]-1,3-dihydro-2H-benzo[f]isoindol-2-yl}phenyl)acetate using the appropriate starting materials.
Ethyl (4-{4-(ethyloxy)-1,3-dioxo-9-[(phenylmethyl)oxy]-1,3-dihydro-2H-benzo[f]isoindol-2-yl}phenyl)acetate (0.10 g, 0.196 mmol) was heated to 100° C. in a 1:1 mixture of acetic acid: 2N aqueous hydrochloric acid (8 ml) for 1 hour. The reaction was cooled to room temperature. On addition of water, the resulting yellow solid was collected by filtration and washed with water. This was purified by MDAP to give the desired product (0.017 g, 0.035 mmol). LC/MS: Rt=3.46, [MH]+ 482.
10% Palladium on carbon (0.365 g) was suspended in ethanol (500 ml), to this was added ethyl (4-{4-[1-methylethoxy]-1,3-dioxo-9-[(phenylmethyl)oxy]-1,3-dihydro-2H-benzo[f]isoindol-2-yl}phenyl)acetate (3.65 g, 6.98 mmol). The reaction was stirred at room temperature under an atmosphere of hydrogen for 3 hours. This was filtered through a bed of celite under a blanket of argon, and washed with ethanol and dichloromethane. The filtrate was evaporated to give an orange solid (3.05 g, 7.04 mmol). LC/MS: Rt=3.72, [MH]+ 434.
The following compounds were prepared in a similar manner to ethyl (4-{4-hydroxy-9-[1-methylethoxy]-1,3-dioxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl}phenyl)acetate using the appropriate starting materials.
To a solution of ethyl (4-{4-hydroxy-9-[1-methylethoxy]-1,3-dioxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl}phenyl)acetate (0.30 g, 0.693 mmols) in dimethylformamide (5 ml), was added potassium carbonate (0.191 g, 1.39 mmol) followed by 1-bromo-2-methylpropane (0.192 g, 1.04 mmol). The reaction was heated to 80° C. for 6 hours. A further addition of 1-bromo-2-methylpropane (0.192 g, 1.04 mmol) was made and heating continued for a further 4 hours. The cooled mixture was partitioned between 2× ethyl acetate and brine, the combined organics were washed with water, dried over sodium sulphate and evaporated down to a yellow oil. This was purified by chromatography on silica gel, eluting with ethyl acetate (0-30%) in hexane to give the title compound as a yellow coloured solid (0.225 g, 0.460 mmol). LC/MS: Rt=4.07, [MH]+ 490.
The following compounds were prepared in a similar manner to ethyl (4-{4-[(-[1-methylethoxyl)-9-[(2-methylpropyl)oxy]-1,3-dioxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl}phenyl)acetate using the appropriate starting materials.
Ethyl (4-{4-[(-[1-methylethoxy]-9-[(2-methylpropyl)oxy]-1,3-dioxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl}phenyl)acetate (0.225 g, 0.460 mmol) was heated to 100° C. in a 1:1 mixture of acetic acid: 2N aqueous hydrochloric acid (10 ml) for 2 hours. The reaction was cooled to room temperature. On addition of water, the resulting yellow solid was collected by filtration and washed with water to give 0.20 g of crude product. 0.10 g was purified by mass directed autoprep to give the title compound (0.076 g, 0.165 mmol). LC/MS: Rt=3.73, [MH]+ 462.
The following compounds were prepared in a similar manner to (4-{4-[1-methylethoxy]-9-[(2-methylpropyl)oxy]-1,3-dioxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl}phenyl)acetic acid using the appropriate starting materials.
To a solution of {4-[4-(butyloxy)-9-(ethyloxy)-1,3-dioxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl]phenyl}acetic acid (0.160 g, 0.358 mmol) in ethanol (3 ml) and tetrahydrofuran (3 ml) cooled to 0° C., was added sodium borohydride (0.041 g, 1.17 mmol) portion wise. The reaction was stirred at 0° C. for 1 hour then a further portion of sodium borohydride (0.041 g, 1.17 mmol) was added, stirring continued at room temperature for 1 hour. The mixture was evaporated and then quenched with aqueous saturated ammonium chloride solution. This was extracted ×2 with ethyl acetate. The aqueous phase was acidified with 2N hydrochloric acid and then re-extracted ×2 with ethyl acetate. The combined organics were washed with brine, dried over magnesium sulphate and evaporated to give the crude product (0.168 g, 0.374 mmol). LC/MS: Rt=3.26, [MH]+ 450.
The following compounds were prepared in a similar manner to {4-[4-(butyloxy)-9-(ethyloxy)-3-hydroxy-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl]phenyl}acetic acid and {4-[4-(butyloxy)-9-(ethyloxy)-1-hydroxy-3-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl]phenyl}acetic acid using the appropriate starting materials.
To a solution of ethyl (4-{4-(methyloxy)-9-[(1-methylpropyl)oxy]-1,3-dioxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl}phenyl)acetate (0.419 g, 0.909 mmol) in ethanol (4 ml) and tetrahydrofuran (8 ml), was added sodium borohydride (0.104 g, 2.74 mmol) portion wise. The reaction was stirred for 1 hour then a further portion of sodium borohydride (0.208 g, 5.47 mmol) was added, stirring continued at room temperature for 1 hour. The mixture was quenched with aqueous saturated ammonium chloride solution and then evaporated. This was extracted ×2 with ethyl acetate, dried over magnesium sulphate and evaporated to give the crude product (0.414 g, 0.894 mmol). LC/MS: Rt=3.59, [MH]+ 464.
To a solution of {4-[4-(butyloxy)-9-(ethyloxy)-3-hydroxy-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl]phenyl}acetic acid and {4-[4-(butyloxy)-9-(ethyloxy)-1-hydroxy-3-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl]phenyl}acetic acid (0.168 g, 0.374 mmol) in trifluoroacetic acid (1 ml) cooled to 0° C., was added triethylsilane (0.089 ml, 0.561 mmol). Stirring continued at 0° C. for 10 minutes, and then the mixture was evaporated. The isomers were separated using supercritical fluid chromatography.
(0.024 g, 0.055 mmol)
LC/MS: Rt=3.52, [MH]+ 434.
(0.042 g, 0.097 mmol)
LC/MS: Rt=3.54, [MH]+434
The following compounds were prepared in a similar manner to {4-[4-(butyloxy)-9-(ethyloxy)-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl]phenyl}acetic acid and {4-[9-(butyloxy)-4-(ethyloxy)-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl]phenyl}acetic acid using the appropriate starting materials.
To a solution of the mixture of ethyl (4-{1-hydroxy-9-[(1-methylethyl)oxy]-4-[(2-methylpropyl)oxy]-3-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl}phenyl)acetic acid and (4-{1-hydroxy-4-[(1-methylethyl)oxy]-9-[(2-methylpropyl)oxy]-3-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl}phenyl)acetic acid (0.114 g, 0.246 mmol) in trifluoroacetic acid (1 ml) cooled to 0° C., was added triethylsilane (0.059 ml, 3.69 mmol). Stirred at 0° C. until the red colour turned to a light yellow colour. This was evaporated. The crude reaction mixture of the two regioisomers were then taken on to the next reaction.
LC/MS: Rt=3.65, [MH]+ 448.
The following compounds were prepared in a similar manner, (4-{4-[(1-methylethyl)oxy]-9-[(2-methylpropyl)oxy]-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl}phenyl)acetic acid-(4-{9-[(1-methylethyl)oxy]-4-[(2-methylpropyl)oxy]-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl}phenyl)acetic acid using the appropriate starting materials.
To a solution of ethyl (4-{1-hydroxy-4-(methyloxy)-9-[(1-methylpropyl)oxy]-3-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl}phenyl)acetate and ethyl (4-{1-hydroxy-9-(methyloxy)-4-[(1-methylpropyl)oxy]-3-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl}phenyl)acetate (0.421 g, 0.909 mmol) in trifluoroacetic acid (5 ml) cooled to 0° C., was added triethylsilane (0.217 ml, 1.36 mmol). Stirring continued at 0° C. for 15 minutes, and then the mixture was evaporated. The crude mixture was purified using chromatography on silica gel, eluting with ethyl acetate (0-30%) in hexane. The isomers were then separated using chiral supercritical fluid chromatography (only one regioisomer was isolated, but the two enantiomers were separated).
(0.018 g, 0.040 mmol)
LC/MS: Rt=4.07, [MH]+ 448.
(0.018 g, 0.040 mmol)
LC/MS: Rt=4.07, [MH]+ 448.
To a solution of (4-{9-[1-methylethoxy]-4-[(2-methylpropyl)oxy]-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl}phenyl)acetic acid and (4-{9-[1-methylethoxy]-4-[(2-methylpropyl)oxy]-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl}phenyl)acetic acid (0.098 g, 0.22 mmol) in ethanol (5 ml) was added 3 drops of concentrated sulphuric acid. This was heated to 100° C. for 30 minutes. The reaction was basified with 880 ammonia and then evaporated. The mixture was partitioned between ×2 dichloromethane and water using a hydrophobic frit. The organic extracts were evaporated down. The isomers were separated using HPLC chromatography.
(0.025 g, 0.053 mmol)
LC/MS: Rt=4.18 [MH]+ 476.
LC/MS: Rt=4.19, [MH]+ 476.
The following compound was prepared in a similar manner to ethyl (4-{9-[1-methylethoxy]-4-[(2-methylpropyl)oxy]-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl}phenyl)acetate and ethyl (4-{4-[1-methylethoxy]-9-[(2-methylpropyl)oxy]-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl}phenyl)acetate using the appropriate starting materials, except using methanol instead of ethanol
To a solution of ethyl (4-{4-(methyloxy)-9-[(1-methylpropyl)oxy]-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl}phenyl)acetate (0.018 g, 0.040 mmol) in ethanol (2 ml) was added 2N aqueous sodium hydroxide solution (2 ml). This was heated to reflux for 1 hour. The ethanol was evaporated and the mixture acidified with 2N aqueous hydrochloric acid. The resulting solid was collected by filtration, washed with water and dried under vacuum to give the title compound (0.016 g, 0.038 mmol). LC/MS: Rt=3.51, [MH]+ 420.
The following compounds were prepared in a similar manner to (4-{4-(methyloxy)-9-[(1-methylpropyl)oxy]-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl}phenyl)acetic acid using the appropriate starting materials. Example 24 was prepared using methanol as a solvent instead of ethanol.
Studies were performed using HEK-293(T) cells expressing the recombinant human prostanoid EP4 receptor (HEK-EP4 cells). Cells were grown as a monolayer culture in DMEM-F12/F12 containing glutamax II (Gibco) and supplemented with 10% foetal bovine serum and 0.4 mg.ml-1 G418. HEK-EP4 cells were pre-treated 24 hr and 30 mins prior to the experiment with 10 μM indomethacin and harvested using Versene containing 10 μM indomethacin. The cells were resuspended in assay buffer (DMEM:F12, 10 μM indomethacin and 200 μM IBMX) at 1×106 cells per ml and incubated for 20 min at 37° C. Thereafter, 50 μl of cells were added to 50 ul agonist (compound of Formula (I)) and incubated at 37° C. for 4 minutes before stopping reactions with 100 μl of 1% triton X-100. cAMP levels in the cell lysates were determined using a competition binding assay. In this assay the ability of cell lysates to inhibit 3H-cAMP (Amersham) binding to the binding subunit of protein kinase A was measured and cAMP levels were calculated from a standard curve. The data for each compound were expressed as a % of the response to a 10 nM maximal concentration of the standard agonist PGE2. For each compound the maximal response and concentration of compound causing 50% of its maximal response were calculated. Intrinsic activity is expressed relative to the maximal response to PGE2. Unless stated, reagents were purchased commercially from Sigma.
The examples of the present invention were tested in the above-mentioned assay and exhibited pEC50 values of 6.4 or higher and intrinsic activities of 30% or higher.
| Number | Date | Country | Kind |
|---|---|---|---|
| 0623203.7 | Nov 2006 | GB | national |
| Filing Document | Filing Date | Country | Kind | 371c Date |
|---|---|---|---|---|
| PCT/EP07/62497 | 11/19/2007 | WO | 00 | 5/21/2009 |
